BioCentury | Jun 29, 2018
Clinical News

Summit discontinues DMD program after Phase II miss

...Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the...
...Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100...
...staining in imaged biopsies and safety Status: Development discontinued Milestone: NA Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Ridinilazole...
BioCentury | Jun 27, 2018
Clinical News

Summit craters after ending DMD program

...Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the...
...off $10.10 (80%) to $2.55 on NASDAQ. PhaseOut DMD enrolled 40 DMD patients ages 5-10. Ezutromid...
...to Summit's Utrophin Modulators" ). Sarepta slipped $6.26 to $129.27 Wednesday. Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Sarepta...
BioCentury | Jan 26, 2018
Clinical News

Summit's ezutromid reduces muscle damage in DMD

...that twice-daily ezutromid (SMT C1100) reduced muscle damage in Duchenne muscular dystrophy patients. Compared to baseline, ezutromid...
...UTRN membrane staining in imaged biopsies and safety. Top-line 48-week data are expected in 3Q18. Ezutromid...
...Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) (formerly BMN 195...
BioCentury | Jan 25, 2018
Clinical News

Summit's ezutromid reduces muscle damage in DMD

...reporting interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100...
...Duchenne muscular dystrophy patients. Summit gained 37.50p (21%) to 215p in London. Compared to baseline, ezutromid...
...ages 5-10 and includes a long-term, extension phase. Top-line 48-week data are expected in 3Q18. Ezutromid...
BioCentury | Oct 13, 2017
Regulation

Seeking surrogates

...dystrophin. That’s a done deal,” Meier told BioCentury. As a small molecule modulator of utrophin, ezutromid...
...measuring utrophin levels as a secondary endpoint in the Phase II PhaseOut DMD trial of ezutromid...
BioCentury | May 19, 2017
Clinical News

Summit completes enrollment in Phase II DMD trial, receives $22M milestone from Sarepta

...Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) completed enrollment in the Phase II PhaseOut DMD trial of ezutromid (SMT C1100...
...trial enrolled 40 ambulatory boys ages 5-10 with DMD to receive twice-daily 2.5 g oral ezutromid...
...Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) (formerly BMN 195...
BioCentury | Oct 10, 2016
Company News

Summit Therapeutics, Sarepta Therapeutics deal

...Summit’s utrophin (UTRN) modulator pipeline to treat Duchenne muscular dystrophy (DMD). The deal includes Summit’s ezutromid...
...up to $482 million in development and regulatory milestones. The milestones comprise $192 million in ezutromid-related...
...the same rate as in the original territories. Sarepta said that all licensed compounds, excluding ezutromid...
BioCentury | Oct 4, 2016
Company News

Sarepta gets territorial rights to Summit's utrophin modulators

...$5.70 (66%) to $14.35 on NASDAQ. The deal includes Summit's lead clinical candidate, ezutromid ( SMT C1100...
...eligible for $482 million in development and regulatory milestones. The milestones comprise $192 million in ezutromid-related...
BioCentury | Oct 3, 2016
Clinical News

Ezutromid regulatory update

...FDA granted rare pediatric disease designation to Summit’s ezutromid to treat Duchenne muscular dystrophy (DMD). The...
...June 27). Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid ( SMT C1100 ) (formerly BMN 195...
BioCentury | Jun 27, 2016
Clinical News

Ezutromid: Phase II started

...Summit began the 48-week, open-label, international Phase II PhaseOut DMD trial to evaluate oral ezutromid in...
...patients ages 5-10. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (formerly SMT C1100 , BMN 195...
Items per page:
1 - 10 of 40